Patents by Inventor James Matthew Symonds
James Matthew Symonds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7481999Abstract: Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: GrantFiled: December 3, 2004Date of Patent: January 27, 2009Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, Barbara J. Gour, James Matthew Symonds, Stephen Byers
-
Patent number: 6962969Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: December 3, 2001Date of Patent: November 8, 2005Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6830894Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 3, 1999Date of Patent: December 14, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Publication number: 20040248219Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: ApplicationFiled: January 16, 2004Publication date: December 9, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Publication number: 20040248220Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: ApplicationFiled: January 16, 2004Publication date: December 9, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Publication number: 20040229811Abstract: Modulating agents for inhibiting or enhancing desmosomal cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a desmosomal cadherin CAR sequence; (b) a non-peptide mimetic of a desmosomal cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a desmosomal cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a desmosomal cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating desmosomal cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: September 3, 2003Publication date: November 18, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6797807Abstract: Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used for cancer therapy or to increase immune cell infiltration into tumors. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by the other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 29, 1999Date of Patent: September 28, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour, J. Steven Alexander
-
Patent number: 6756356Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 3, 1998Date of Patent: June 29, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6723700Abstract: Method for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequence recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: March 30, 1999Date of Patent: April 20, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6682901Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: GrantFiled: May 5, 1999Date of Patent: January 27, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Patent number: 6680175Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: GrantFiled: January 20, 1999Date of Patent: January 20, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Publication number: 20030229199Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: March 21, 2003Publication date: December 11, 2003Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6638911Abstract: Modulating agents for inhibiting or enhancing desmosomal cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a desmosomal cadherin CAR sequence; (b) a non-peptide mimetic of a desmosomal cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a desmosomal cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a desmosomal cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating desmosomal cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: March 27, 2000Date of Patent: October 28, 2003Assignee: Adherex Technologies Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6593297Abstract: Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: GrantFiled: March 8, 1999Date of Patent: July 15, 2003Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Patent number: 6569996Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: April 20, 2001Date of Patent: May 27, 2003Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Publication number: 20030096746Abstract: Agents for inhibiting cancer metastasis are provided.Type: ApplicationFiled: May 7, 2002Publication date: May 22, 2003Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Publication number: 20030027761Abstract: Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds thee JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: ApplicationFiled: April 8, 2002Publication date: February 6, 2003Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Publication number: 20020193294Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: ApplicationFiled: November 3, 1998Publication date: December 19, 2002Inventors: OREST W. BLASCHUK, JAMES MATTHEW SYMONDS, BARBARA J. GOUR
-
Publication number: 20020169106Abstract: Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: ApplicationFiled: March 8, 1999Publication date: November 14, 2002Inventors: OREST W. BLASCHUK, STEPHEN BYERS, BARBARA J. GOUR, JAMES MATTHEW SYMONDS
-
Patent number: 6472367Abstract: Modulating agents for inhibiting or enhancing OB-cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) an OB-cadherin CAR sequence; (b) a peptide analogue or peptidomimetic thereof; (c) an antibody or antigen-binding fragment thereof that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding any of the foregoing peptide sequences. Methods for using such modulating agents for modulating OB-cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: May 5, 1998Date of Patent: October 29, 2002Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour